Canada

Health Canada says it has approved 354 Special Access requests for psilocybin since 2022.

These are practitioners’ requests: one can cover several patients, and one patient can need several. Patients cannot apply directly, and a yes does not oblige a manufacturer to supply.

Analysis · Finding · By Allan Kerr · Checked 6 October 2026

In brief

  • The yearly figures Health Canada gave Parliament in September 2026 add up to 354 Special Access Program applications for psilocybin approved from 2022 into 2026. Other published yearly figures differ.
  • Each is an application, not a person. One request can cover several patients, and one patient can need several requests. The 2026 figure is for part of the year.
  • Only a practitioner can ask, for a patient with a serious or life-threatening condition; patients cannot apply directly. Health Canada decides case by case and says there is no guarantee.

When Health Canada’s Special Access Program (opens in new tab) approves a request for psilocybin, it faxes a letter of authorization to the drug’s manufacturer and sends a copy to the practitioner who asked. The letter allows a sale, and whether it happens is up to the manufacturer.

On 21 September 2026 the department put its own count of those decisions on the parliamentary record. In a written reply (opens in new tab) to a question from MP Dan Mazier, it counted the applications it received, approved and denied in each calendar year since 2016. Its yearly figures do not match those published earlier.

Limits of this count

  • It adds up applications to the Special Access Program, as Health Canada reported them to Parliament, and does not count people.
  • It leaves out requests that were cancelled, withdrawn or deemed incomplete, three of the five decisions Health Canada lists for a request.
  • It covers one legal route. Individual exemptions and clinical trials are separate.
  • The 2026 figure covers part of the year, and the reply gives no cut-off date.
  • An approval authorizes a sale to a practitioner and makes no finding about whether a treatment worked.

This page is not medical or legal advice, and it does not list clinics, practitioners or products. If you or someone you know is thinking about suicide, call or text 9-8-8, at any hour, anywhere in Canada.

Approvals by year

The yearly figures in Health Canada’s reply to Parliament, Sessional Paper 8555-451-1384 (opens in new tab), add up to 354 Special Access applications for psilocybin approved from 2022 into 2026.

Psilocybin applications to Health Canada’s Special Access Program, by year

As reported to Parliament. These are applications, not people. The table leaves out requests that were cancelled, withdrawn or deemed incomplete. For 157 of the applications it counts as received, it records neither an approval nor a denial, and it does not say why. 2026 is a part year with no cut-off date stated, so it is not drawn. None were approved from 2016 to 2021, when regulations barred approval.

Applications20222023202420252026, part year
Approved581121195114
Denied052120
Received7115217710930

Source: Sessional Paper 8555-451-1384 (opens in new tab), tabled 21 September 2026, transcribed by The Psilocybin Record. Other published yearly figures differ. Download the table (CSV)

Notes on the table

Every row is zero from 2016 to 2021. The reply notes that the table “excludes requests that were cancelled, withdrawn, or deemed incomplete” and gives no cut-off date for 2026. In a June 2026 reply (opens in new tab) about the Program as a whole, Health Canada told Parliament that requests “may or may not have been processed in the same year”. The paper was tabled 21 September 2026.

The table records 28 denials, and withdrawn requests are outside it: Health Canada’s guidance (opens in new tab) says a practitioner “may choose to withdraw the request rather than receiving a denial”.

From 2 October 2013 the Food and Drug Regulations barred Health Canada (opens in new tab) from issuing a letter of authorization for any restricted drug, a category that included psilocybin. An amendment published on 5 January 2022 (opens in new tab) repealed the bar.

Who can ask

Ink and wash drawing on cream paper. A dark boxy machine feeds a long curling strip of paper across a table. Near its end, a cluster of slender tan mushrooms grows out of the paper, roots spreading across it, beside a large red wax seal pressed with a maple leaf.
The Program’s answer is a letter. The drug comes from a manufacturer, if the manufacturer agrees to sell.Illustration for The Psilocybin Record

Only a practitioner can apply, for a patient under their care. Health Canada’s information for patients (opens in new tab) says applicants are “typically physicians” and that “Patients cannot apply directly.” A request has to be for a serious or life-threatening condition where conventional treatments have failed, are unsuitable or are unavailable in Canada.

The department decides each request case by case. Its notice on psychedelic requests (opens in new tab) says the Program considers whether conventional treatments “have been tried and have failed or have been considered and deemed not appropriate for that patient”. It adds that Health Canada’s role “is not to question the practitioner’s diagnosis or recommended treatment option”.

Health Canada’s psilocybin page (opens in new tab) says “There is no guarantee that a request for psilocybin, or any other unauthorized drug, will be granted”. The reply to Parliament gives no breakdown by condition.

One request is not one patient. The guidance says the Program’s patient request form, Form A, “is used to request access to a drug for immediate use for one or multiple patient(s)”. For psychedelic requests the notice asks for a patient-specific form, and “new or repeat requests” both need one.

An approval, in the notice’s words, “is not a broad statement or opinion that the drug is safe, efficacious or of high quality, rather, that the sale is justifiable in the context of a medical emergency”. The Program asks the manufacturer named in the request to confirm it is “able and willing to sell the drug”. The guidance says Health Canada “cannot compel a manufacturer” to sell.

The routes this count leaves out

Health Canada says (opens in new tab) “In some circumstances, with the support of a regulated health care practitioner, it may be possible for individuals to legally access psilocybin through one of three pathways”. This count covers one of them.

Clinical trials

Health Canada says
a trial “should be the first legal route pursued” and that people who want to take part “should talk to their health care provider”.
Count
42 registered trials in our corpus list a Canadian site, and 21 were recruiting as the corpus stood on 16 November 2026. The count is of trials, not places for participants.

Special Access Program

How it works
A practitioner applies for a patient, and Health Canada decides case by case.
Count
354 applications approved from 2022 into 2026, the sum of the yearly figures in the reply to Parliament.

Individual exemption

How it works
Under subsection 56(1) (opens in new tab) of the Controlled Drugs and Substances Act, decided by the Minister of Health.
Health Canada says
the other two routes “should generally be pursued instead of an individual exemption under the CDSA, unless it can be demonstrated that access to psilocybin is not possible or suitable through these existing legal routes”.

The Program’s letter of authorization is still issued under the Food and Drug Regulations (opens in new tab), and since 1 October 2026 the Controlled Substances Regulations (opens in new tab) let the practitioner named in it sell, provide or administer a restricted drug to the patient they are treating. Canada’s entry in the register carries the rest of the law.

Earlier counts

Two sets of yearly figures were published before the reply, and neither matches it in any year. In June 2025 CBC News printed (opens in new tab) yearly counts of authorized requests without stating their source. In a comment in the July 2025 issue of Nature Mental Health (opens in new tab), Quebec researchers published figures released to them under an access-to-information request. Unlike the reply, those figures were broken down by condition.

Approved or authorized requests for psilocybin, by source and year, with the total each source gives
202220232024Total it gives
CBC News, June 2025, source not stated
56106104301, to 18 June 2025
Access-to-information figures, Nature Mental Health, July 2025 issue
74123107304, 2022 to 2024
Reply to Parliament, 21 September 2026
58112119354, 2022 into 2026, no cut-off date stated
CBC Radio, 7 April 2026, “according to data from Health Canada”
338, 1 January 2022 to 25 February 2026
Health Canada spokesperson, as reported by CBC, 16 June 2026
354, since January 2022
Approved or authorized requests for psilocybin under the Special Access Program, as each source gives them. The windows differ, and no source explains the differences.

CBC reported on 16 June 2026 (opens in new tab) that a Health Canada spokesperson said the department had issued 354 authorizations for psilocybin since January 2022, the same total the reply’s yearly figures add up to.

Health Canada ends each approval with a letter, faxed to a manufacturer and copied to a practitioner. The yearly figures in its reply to Parliament add up to 354 approvals. How many patients they covered, the reply does not say.

Notes

Health Canada’s information for patients (opens in new tab) describes the Program in the department’s own words. If you or someone you know is thinking about suicide, call or text 9-8-8.

Related. Canada in the register · How many Australians have been prescribed psilocybin? · Clinical trials · Alerts